You are here:

Bayer plc/Bayer Schering Pharma

Name SMC ID No Status Sub. Type
 
aflibercept (Eylea) 857/13 Accepted Full submission
aflibercept (Eylea) 1186/16 Accepted Full submission
aflibercept (Eylea) 1003/14 Restricted Full submission
aflibercept (Eylea) 1074/15 Accepted Full submission
aflibercept intravitreal (Eylea®) 954/14 Accepted Full submission
alemtuzumab (MabCampath) 494/08 Marketing Authorisation Withdrawn Full submission
cannabinoid (Sativex) 703/11 Not Recommended Non submission
estradiol / dienogest (Qlaira) 583/09 Not Recommended Non submission
ethinylestradiol with drosperinone (Yasmin) 23/03 Not Recommended Resubmission
ibritumomab tiuxetan 1.6mg/ml (Zevalin) 499/08 Not Recommended Non submission
levonorgestrel (Jaydess) 1036/15 Accepted Full submission
moxifloxacin (Avelox IV) 650/10 Restricted Full submission
Moxifloxacin (Avelox®) 70/03 Restricted Full submission
Moxifloxacin (Avelox®) 69/03 Restricted Full submission
radium 223 (Xofigo) 1077/15 Accepted Full submission
regorafenib (Stivarga) 1118/15 Not Recommended Non submission
regorafenib (Stivarga) 1031/15 Accepted Full submission
riociguat (Adempas) 1001/14 Restricted Full submission
riociguat (Adempas) 1056/15 Restricted Full submission
rivaroxaban (Xarelto) 519/08 Accepted Full submission
rivaroxaban (Xarelto) 852/13 Accepted Full submission
rivaroxaban (Xarelto) 1062/15 Not Recommended Full submission
rivaroxaban (Xarelto) atrial 756/12 Restricted Full submission
rivaroxaban (Xarelto) DVT 755/12 Accepted Full submission
sorafenib (Nexavar) 1055/15 Accepted Full submission
sorafenib (Nexavar) 482/08 Not Recommended Full submission
sorafenib (Nexavar) 482/08 Not Recommended Resubmission
sorafenib (Nexavar) 482/08 Restricted Resubmission
sorafenib 200mg tablets (Nexavar) 321/06 Superseded Full submission
testosterone undecanoate (Nebido) 308/06 Accepted Full submission
vardenafil (Levitra) 727/11 Restricted Full submission

Back